Download Your Complimentary Copy of the 2026 Agenda
The 10th Complement-Based Drug Development Summit is your unique forum to learn, network and partner with the brightest minds revolutionizing the complement therapeutics.
Who's Attending
60+ Experts Dedicated to Complement Biology Across Biopharma & Academia Sharing Insights Across Next-Generation Modalities
New Content for 2026
Explore siRNA, Gene Therapy & Biologics Approaches Across CNS, Ocular and Autoimmune Indications, Over 18+ Data Presentations
Networking Opportunities
8+ Hours of In-Person Networking Dedicated to Forming Valuable Connections that Last Long After the Event Ends
Pre-Conference Workshops
2 Discussed-Led, Interactive Workshops Exploring Emerging Targets Beyond C3 & C5, and Rarget Engagement Measurement
Presentation Opportunities
1 Scientific Poster Session to Share Your Latest Work and Connect With Peers Through Meaningful Discussion
80+
Experts Dedicated to Complement
18+
Data-Driven Presentations
7+
Hours of In-Person Networking
2
Discussed-Led, Interactive Workshops
1
Scientific Poster Session
Having trouble downloading the brochure? Let us know and we’ll email it to you instead.
Download The 2026 Scientific Program
Attending Companies Include
What's New for 2026?
The Complement-Based Drug Development Summit returns for its 10th year with refreshed content designed to help developers navigate the next era of complement therapeutics. As the field expands beyond C3 and C5 inhibition, the 2026 agenda explores emerging targets, novel modalities, and new opportunities across ophthalmology, neurodegeneration, oncology, autoimmune disease, and beyond:
- Expanded focus on next-generation complement targets, including Factor B, Factor H and C1q
- Broader discussion of complement approaches across CNS, ocular, oncology and autoimmune indications
- New speaker perspectives from emerging biotech innovators and researchers
- Enhanced coverage of siRNA, gene therapy, biologics and small molecule approaches
- Interactive workshops focused on target selection and modality strategy
New Companies on the 2026 Agenda: